Pharma & Healthcare
Global IL-17 Monoclonal Antibody Injections Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 569218
- Pages: 126
- Figures: 115
- Views: 8
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global IL-17 Monoclonal Antibody Injections market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Novartis
UCB
Eli Lilly and Co.
AstraZeneca
Segment by Type
Human Origin
Rat Origin
Other
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the IL-17 Monoclonal Antibody Injections study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global IL-17 Monoclonal Antibody Injections market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Novartis
UCB
Eli Lilly and Co.
AstraZeneca
Segment by Type
Human Origin
Rat Origin
Other
Segment by Application
Hospital
Clinic
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the IL-17 Monoclonal Antibody Injections study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to IL-17 Monoclonal Antibody Injections: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global IL-17 Monoclonal Antibody Injections Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Human Origin
1.2.3 Rat Origin
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global IL-17 Monoclonal Antibody Injections Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global IL-17 Monoclonal Antibody Injections Revenue Estimates and Forecasts 2020-2031
2.2 Global IL-17 Monoclonal Antibody Injections Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global IL-17 Monoclonal Antibody Injections Sales Estimates and Forecasts 2020-2031
2.4 Global IL-17 Monoclonal Antibody Injections Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global IL-17 Monoclonal Antibody Injections Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global IL-17 Monoclonal Antibody Injections Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Human Origin Market Size by Manufacturers
3.5.2 Rat Origin Market Size by Manufacturers
3.5.3 Other Market Size by Manufacturers
3.6 Global IL-17 Monoclonal Antibody Injections Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global IL-17 Monoclonal Antibody Injections Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global IL-17 Monoclonal Antibody Injections Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global IL-17 Monoclonal Antibody Injections Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global IL-17 Monoclonal Antibody Injections Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
6.4 North America IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America IL-17 Monoclonal Antibody Injections Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
7.4 Europe IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe IL-17 Monoclonal Antibody Injections Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific IL-17 Monoclonal Antibody Injections Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
9.4 Central and South America IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America IL-17 Monoclonal Antibody Injections Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa IL-17 Monoclonal Antibody Injections Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis IL-17 Monoclonal Antibody Injections Product Models, Descriptions and Specifications
11.1.4 Novartis IL-17 Monoclonal Antibody Injections Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Novartis IL-17 Monoclonal Antibody Injections Sales by Product in 2024
11.1.6 Novartis IL-17 Monoclonal Antibody Injections Sales by Application in 2024
11.1.7 Novartis IL-17 Monoclonal Antibody Injections Sales by Geographic Area in 2024
11.1.8 Novartis IL-17 Monoclonal Antibody Injections SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 UCB
11.2.1 UCB Corporation Information
11.2.2 UCB Business Overview
11.2.3 UCB IL-17 Monoclonal Antibody Injections Product Models, Descriptions and Specifications
11.2.4 UCB IL-17 Monoclonal Antibody Injections Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 UCB IL-17 Monoclonal Antibody Injections Sales by Product in 2024
11.2.6 UCB IL-17 Monoclonal Antibody Injections Sales by Application in 2024
11.2.7 UCB IL-17 Monoclonal Antibody Injections Sales by Geographic Area in 2024
11.2.8 UCB IL-17 Monoclonal Antibody Injections SWOT Analysis
11.2.9 UCB Recent Developments
11.3 Eli Lilly and Co.
11.3.1 Eli Lilly and Co. Corporation Information
11.3.2 Eli Lilly and Co. Business Overview
11.3.3 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Product Models, Descriptions and Specifications
11.3.4 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales by Product in 2024
11.3.6 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales by Application in 2024
11.3.7 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales by Geographic Area in 2024
11.3.8 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections SWOT Analysis
11.3.9 Eli Lilly and Co. Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca IL-17 Monoclonal Antibody Injections Product Models, Descriptions and Specifications
11.4.4 AstraZeneca IL-17 Monoclonal Antibody Injections Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 AstraZeneca IL-17 Monoclonal Antibody Injections Sales by Product in 2024
11.4.6 AstraZeneca IL-17 Monoclonal Antibody Injections Sales by Application in 2024
11.4.7 AstraZeneca IL-17 Monoclonal Antibody Injections Sales by Geographic Area in 2024
11.4.8 AstraZeneca IL-17 Monoclonal Antibody Injections SWOT Analysis
11.4.9 AstraZeneca Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 IL-17 Monoclonal Antibody Injections Industry Chain
12.2 IL-17 Monoclonal Antibody Injections Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 IL-17 Monoclonal Antibody Injections Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 IL-17 Monoclonal Antibody Injections Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 IL-17 Monoclonal Antibody Injections Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global IL-17 Monoclonal Antibody Injections Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to IL-17 Monoclonal Antibody Injections: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global IL-17 Monoclonal Antibody Injections Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Human Origin
1.2.3 Rat Origin
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global IL-17 Monoclonal Antibody Injections Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global IL-17 Monoclonal Antibody Injections Revenue Estimates and Forecasts 2020-2031
2.2 Global IL-17 Monoclonal Antibody Injections Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global IL-17 Monoclonal Antibody Injections Sales Estimates and Forecasts 2020-2031
2.4 Global IL-17 Monoclonal Antibody Injections Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global IL-17 Monoclonal Antibody Injections Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global IL-17 Monoclonal Antibody Injections Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Human Origin Market Size by Manufacturers
3.5.2 Rat Origin Market Size by Manufacturers
3.5.3 Other Market Size by Manufacturers
3.6 Global IL-17 Monoclonal Antibody Injections Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global IL-17 Monoclonal Antibody Injections Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global IL-17 Monoclonal Antibody Injections Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global IL-17 Monoclonal Antibody Injections Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global IL-17 Monoclonal Antibody Injections Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
6.4 North America IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America IL-17 Monoclonal Antibody Injections Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
7.4 Europe IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe IL-17 Monoclonal Antibody Injections Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific IL-17 Monoclonal Antibody Injections Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
9.4 Central and South America IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America IL-17 Monoclonal Antibody Injections Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa IL-17 Monoclonal Antibody Injections Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa IL-17 Monoclonal Antibody Injections Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa IL-17 Monoclonal Antibody Injections Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis IL-17 Monoclonal Antibody Injections Product Models, Descriptions and Specifications
11.1.4 Novartis IL-17 Monoclonal Antibody Injections Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Novartis IL-17 Monoclonal Antibody Injections Sales by Product in 2024
11.1.6 Novartis IL-17 Monoclonal Antibody Injections Sales by Application in 2024
11.1.7 Novartis IL-17 Monoclonal Antibody Injections Sales by Geographic Area in 2024
11.1.8 Novartis IL-17 Monoclonal Antibody Injections SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 UCB
11.2.1 UCB Corporation Information
11.2.2 UCB Business Overview
11.2.3 UCB IL-17 Monoclonal Antibody Injections Product Models, Descriptions and Specifications
11.2.4 UCB IL-17 Monoclonal Antibody Injections Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 UCB IL-17 Monoclonal Antibody Injections Sales by Product in 2024
11.2.6 UCB IL-17 Monoclonal Antibody Injections Sales by Application in 2024
11.2.7 UCB IL-17 Monoclonal Antibody Injections Sales by Geographic Area in 2024
11.2.8 UCB IL-17 Monoclonal Antibody Injections SWOT Analysis
11.2.9 UCB Recent Developments
11.3 Eli Lilly and Co.
11.3.1 Eli Lilly and Co. Corporation Information
11.3.2 Eli Lilly and Co. Business Overview
11.3.3 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Product Models, Descriptions and Specifications
11.3.4 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales by Product in 2024
11.3.6 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales by Application in 2024
11.3.7 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections Sales by Geographic Area in 2024
11.3.8 Eli Lilly and Co. IL-17 Monoclonal Antibody Injections SWOT Analysis
11.3.9 Eli Lilly and Co. Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca IL-17 Monoclonal Antibody Injections Product Models, Descriptions and Specifications
11.4.4 AstraZeneca IL-17 Monoclonal Antibody Injections Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 AstraZeneca IL-17 Monoclonal Antibody Injections Sales by Product in 2024
11.4.6 AstraZeneca IL-17 Monoclonal Antibody Injections Sales by Application in 2024
11.4.7 AstraZeneca IL-17 Monoclonal Antibody Injections Sales by Geographic Area in 2024
11.4.8 AstraZeneca IL-17 Monoclonal Antibody Injections SWOT Analysis
11.4.9 AstraZeneca Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 IL-17 Monoclonal Antibody Injections Industry Chain
12.2 IL-17 Monoclonal Antibody Injections Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 IL-17 Monoclonal Antibody Injections Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 IL-17 Monoclonal Antibody Injections Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 IL-17 Monoclonal Antibody Injections Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global IL-17 Monoclonal Antibody Injections Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global IL-17 Monoclonal Antibody Injections Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global IL-17 Monoclonal Antibody Injections Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global IL-17 Monoclonal Antibody Injections Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global IL-17 Monoclonal Antibody Injections Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global IL-17 Monoclonal Antibody Injections Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global IL-17 Monoclonal Antibody Injections Sales by Region (2020-2025) & (K Units)
Table 8. Global IL-17 Monoclonal Antibody Injections Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global IL-17 Monoclonal Antibody Injections Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global IL-17 Monoclonal Antibody Injections Sales Share by Manufacturers (2020-2025)
Table 12. Global IL-17 Monoclonal Antibody Injections Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global IL-17 Monoclonal Antibody Injections Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global IL-17 Monoclonal Antibody Injections by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IL-17 Monoclonal Antibody Injections as of 2024)
Table 16. Global IL-17 Monoclonal Antibody Injections Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global IL-17 Monoclonal Antibody Injections Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers IL-17 Monoclonal Antibody Injections Manufacturing Base and Headquarters
Table 19. Global IL-17 Monoclonal Antibody Injections Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global IL-17 Monoclonal Antibody Injections Sales by Type (2020-2025) & (K Units)
Table 23. Global IL-17 Monoclonal Antibody Injections Sales by Type (2026-2031) & (K Units)
Table 24. Global IL-17 Monoclonal Antibody Injections Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global IL-17 Monoclonal Antibody Injections Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global IL-17 Monoclonal Antibody Injections ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global IL-17 Monoclonal Antibody Injections Sales by Application (2020-2025) & (K Units)
Table 29. Global IL-17 Monoclonal Antibody Injections Sales by Application (2026-2031) & (K Units)
Table 30. IL-17 Monoclonal Antibody Injections High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global IL-17 Monoclonal Antibody Injections Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global IL-17 Monoclonal Antibody Injections Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global IL-17 Monoclonal Antibody Injections ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America IL-17 Monoclonal Antibody Injections Growth Accelerators and Market Barriers
Table 37. North America IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America IL-17 Monoclonal Antibody Injections Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe IL-17 Monoclonal Antibody Injections Growth Accelerators and Market Barriers
Table 40. Europe IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe IL-17 Monoclonal Antibody Injections Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific IL-17 Monoclonal Antibody Injections Growth Accelerators and Market Barriers
Table 45. Southeast Asia IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America IL-17 Monoclonal Antibody Injections Investment Opportunities and Key Challenges
Table 47. Central and South America IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa IL-17 Monoclonal Antibody Injections Investment Opportunities and Key Challenges
Table 49. Middle East and Africa IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Novartis Corporation Information
Table 51. Novartis Description and Major Businesses
Table 52. Novartis Product Models, Descriptions and Specifications
Table 53. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Novartis Sales Value Proportion by Product in 2024
Table 55. Novartis Sales Value Proportion by Application in 2024
Table 56. Novartis Sales Value Proportion by Geographic Area in 2024
Table 57. Novartis IL-17 Monoclonal Antibody Injections SWOT Analysis
Table 58. Novartis Recent Developments
Table 59. UCB Corporation Information
Table 60. UCB Description and Major Businesses
Table 61. UCB Product Models, Descriptions and Specifications
Table 62. UCB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. UCB Sales Value Proportion by Product in 2024
Table 64. UCB Sales Value Proportion by Application in 2024
Table 65. UCB Sales Value Proportion by Geographic Area in 2024
Table 66. UCB IL-17 Monoclonal Antibody Injections SWOT Analysis
Table 67. UCB Recent Developments
Table 68. Eli Lilly and Co. Corporation Information
Table 69. Eli Lilly and Co. Description and Major Businesses
Table 70. Eli Lilly and Co. Product Models, Descriptions and Specifications
Table 71. Eli Lilly and Co. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Eli Lilly and Co. Sales Value Proportion by Product in 2024
Table 73. Eli Lilly and Co. Sales Value Proportion by Application in 2024
Table 74. Eli Lilly and Co. Sales Value Proportion by Geographic Area in 2024
Table 75. Eli Lilly and Co. IL-17 Monoclonal Antibody Injections SWOT Analysis
Table 76. Eli Lilly and Co. Recent Developments
Table 77. AstraZeneca Corporation Information
Table 78. AstraZeneca Description and Major Businesses
Table 79. AstraZeneca Product Models, Descriptions and Specifications
Table 80. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. AstraZeneca Sales Value Proportion by Product in 2024
Table 82. AstraZeneca Sales Value Proportion by Application in 2024
Table 83. AstraZeneca Sales Value Proportion by Geographic Area in 2024
Table 84. AstraZeneca IL-17 Monoclonal Antibody Injections SWOT Analysis
Table 85. AstraZeneca Recent Developments
Table 86. Key Raw Materials Distribution
Table 87. Raw Materials Key Suppliers
Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 89. Milestones in Production Technology Evolution
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. IL-17 Monoclonal Antibody Injections Product Picture
Figure 2. Global IL-17 Monoclonal Antibody Injections Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Human Origin Product Picture
Figure 4. Rat Origin Product Picture
Figure 5. Other Product Picture
Figure 6. Global IL-17 Monoclonal Antibody Injections Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Other
Figure 10. IL-17 Monoclonal Antibody Injections Report Years Considered
Figure 11. Global IL-17 Monoclonal Antibody Injections Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 13. Global IL-17 Monoclonal Antibody Injections Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global IL-17 Monoclonal Antibody Injections Revenue Market Share by Region (2020-2031)
Figure 15. Global IL-17 Monoclonal Antibody Injections Sales (2020-2031) & (K Units)
Figure 16. Global IL-17 Monoclonal Antibody Injections Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers IL-17 Monoclonal Antibody Injections Sales Volume Market Share in 2024
Figure 19. Global IL-17 Monoclonal Antibody Injections Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Human Origin Revenue Market Share by Manufacturer in 2024
Figure 22. Rat Origin Revenue Market Share by Manufacturer in 2024
Figure 23. Other Revenue Market Share by Manufacturer in 2024
Figure 24. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Type (2020-2031)
Figure 25. Global IL-17 Monoclonal Antibody Injections Revenue Market Share by Type (2020-2031)
Figure 26. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Application (2020-2031)
Figure 27. Global IL-17 Monoclonal Antibody Injections Revenue Market Share by Application (2020-2031)
Figure 28. North America IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 29. North America IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 31. North America IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 36. Canada IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 38. Europe IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 39. Europe IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 41. Europe IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 46. France IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 48. Italy IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 49. Russia IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 58. Japan IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 61. India IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 82. IL-17 Monoclonal Antibody Injections Industry Chain Mapping
Figure 83. Regional IL-17 Monoclonal Antibody Injections Manufacturing Base Distribution (%)
Figure 84. Global IL-17 Monoclonal Antibody Injections Production Market Share by Region (2020-2031)
Figure 85. IL-17 Monoclonal Antibody Injections Production Process
Figure 86. Regional IL-17 Monoclonal Antibody Injections Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Table 1. Global IL-17 Monoclonal Antibody Injections Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global IL-17 Monoclonal Antibody Injections Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global IL-17 Monoclonal Antibody Injections Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global IL-17 Monoclonal Antibody Injections Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global IL-17 Monoclonal Antibody Injections Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global IL-17 Monoclonal Antibody Injections Sales by Region (2020-2025) & (K Units)
Table 8. Global IL-17 Monoclonal Antibody Injections Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global IL-17 Monoclonal Antibody Injections Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global IL-17 Monoclonal Antibody Injections Sales Share by Manufacturers (2020-2025)
Table 12. Global IL-17 Monoclonal Antibody Injections Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global IL-17 Monoclonal Antibody Injections Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global IL-17 Monoclonal Antibody Injections by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IL-17 Monoclonal Antibody Injections as of 2024)
Table 16. Global IL-17 Monoclonal Antibody Injections Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global IL-17 Monoclonal Antibody Injections Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers IL-17 Monoclonal Antibody Injections Manufacturing Base and Headquarters
Table 19. Global IL-17 Monoclonal Antibody Injections Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global IL-17 Monoclonal Antibody Injections Sales by Type (2020-2025) & (K Units)
Table 23. Global IL-17 Monoclonal Antibody Injections Sales by Type (2026-2031) & (K Units)
Table 24. Global IL-17 Monoclonal Antibody Injections Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global IL-17 Monoclonal Antibody Injections Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global IL-17 Monoclonal Antibody Injections ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global IL-17 Monoclonal Antibody Injections Sales by Application (2020-2025) & (K Units)
Table 29. Global IL-17 Monoclonal Antibody Injections Sales by Application (2026-2031) & (K Units)
Table 30. IL-17 Monoclonal Antibody Injections High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global IL-17 Monoclonal Antibody Injections Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global IL-17 Monoclonal Antibody Injections Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global IL-17 Monoclonal Antibody Injections ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America IL-17 Monoclonal Antibody Injections Growth Accelerators and Market Barriers
Table 37. North America IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America IL-17 Monoclonal Antibody Injections Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe IL-17 Monoclonal Antibody Injections Growth Accelerators and Market Barriers
Table 40. Europe IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe IL-17 Monoclonal Antibody Injections Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific IL-17 Monoclonal Antibody Injections Growth Accelerators and Market Barriers
Table 45. Southeast Asia IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America IL-17 Monoclonal Antibody Injections Investment Opportunities and Key Challenges
Table 47. Central and South America IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa IL-17 Monoclonal Antibody Injections Investment Opportunities and Key Challenges
Table 49. Middle East and Africa IL-17 Monoclonal Antibody Injections Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Novartis Corporation Information
Table 51. Novartis Description and Major Businesses
Table 52. Novartis Product Models, Descriptions and Specifications
Table 53. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Novartis Sales Value Proportion by Product in 2024
Table 55. Novartis Sales Value Proportion by Application in 2024
Table 56. Novartis Sales Value Proportion by Geographic Area in 2024
Table 57. Novartis IL-17 Monoclonal Antibody Injections SWOT Analysis
Table 58. Novartis Recent Developments
Table 59. UCB Corporation Information
Table 60. UCB Description and Major Businesses
Table 61. UCB Product Models, Descriptions and Specifications
Table 62. UCB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. UCB Sales Value Proportion by Product in 2024
Table 64. UCB Sales Value Proportion by Application in 2024
Table 65. UCB Sales Value Proportion by Geographic Area in 2024
Table 66. UCB IL-17 Monoclonal Antibody Injections SWOT Analysis
Table 67. UCB Recent Developments
Table 68. Eli Lilly and Co. Corporation Information
Table 69. Eli Lilly and Co. Description and Major Businesses
Table 70. Eli Lilly and Co. Product Models, Descriptions and Specifications
Table 71. Eli Lilly and Co. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Eli Lilly and Co. Sales Value Proportion by Product in 2024
Table 73. Eli Lilly and Co. Sales Value Proportion by Application in 2024
Table 74. Eli Lilly and Co. Sales Value Proportion by Geographic Area in 2024
Table 75. Eli Lilly and Co. IL-17 Monoclonal Antibody Injections SWOT Analysis
Table 76. Eli Lilly and Co. Recent Developments
Table 77. AstraZeneca Corporation Information
Table 78. AstraZeneca Description and Major Businesses
Table 79. AstraZeneca Product Models, Descriptions and Specifications
Table 80. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. AstraZeneca Sales Value Proportion by Product in 2024
Table 82. AstraZeneca Sales Value Proportion by Application in 2024
Table 83. AstraZeneca Sales Value Proportion by Geographic Area in 2024
Table 84. AstraZeneca IL-17 Monoclonal Antibody Injections SWOT Analysis
Table 85. AstraZeneca Recent Developments
Table 86. Key Raw Materials Distribution
Table 87. Raw Materials Key Suppliers
Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 89. Milestones in Production Technology Evolution
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. IL-17 Monoclonal Antibody Injections Product Picture
Figure 2. Global IL-17 Monoclonal Antibody Injections Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Human Origin Product Picture
Figure 4. Rat Origin Product Picture
Figure 5. Other Product Picture
Figure 6. Global IL-17 Monoclonal Antibody Injections Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Other
Figure 10. IL-17 Monoclonal Antibody Injections Report Years Considered
Figure 11. Global IL-17 Monoclonal Antibody Injections Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 13. Global IL-17 Monoclonal Antibody Injections Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global IL-17 Monoclonal Antibody Injections Revenue Market Share by Region (2020-2031)
Figure 15. Global IL-17 Monoclonal Antibody Injections Sales (2020-2031) & (K Units)
Figure 16. Global IL-17 Monoclonal Antibody Injections Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers IL-17 Monoclonal Antibody Injections Sales Volume Market Share in 2024
Figure 19. Global IL-17 Monoclonal Antibody Injections Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Human Origin Revenue Market Share by Manufacturer in 2024
Figure 22. Rat Origin Revenue Market Share by Manufacturer in 2024
Figure 23. Other Revenue Market Share by Manufacturer in 2024
Figure 24. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Type (2020-2031)
Figure 25. Global IL-17 Monoclonal Antibody Injections Revenue Market Share by Type (2020-2031)
Figure 26. Global IL-17 Monoclonal Antibody Injections Sales Market Share by Application (2020-2031)
Figure 27. Global IL-17 Monoclonal Antibody Injections Revenue Market Share by Application (2020-2031)
Figure 28. North America IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 29. North America IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 31. North America IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 36. Canada IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 38. Europe IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 39. Europe IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 41. Europe IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 46. France IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 48. Italy IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 49. Russia IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 58. Japan IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 61. India IL-17 Monoclonal Antibody Injections Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa IL-17 Monoclonal Antibody Injections Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa IL-17 Monoclonal Antibody Injections Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa IL-17 Monoclonal Antibody Injections Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa IL-17 Monoclonal Antibody Injections Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa IL-17 Monoclonal Antibody Injections Revenue (2020-2025) & (US$ Million)
Figure 82. IL-17 Monoclonal Antibody Injections Industry Chain Mapping
Figure 83. Regional IL-17 Monoclonal Antibody Injections Manufacturing Base Distribution (%)
Figure 84. Global IL-17 Monoclonal Antibody Injections Production Market Share by Region (2020-2031)
Figure 85. IL-17 Monoclonal Antibody Injections Production Process
Figure 86. Regional IL-17 Monoclonal Antibody Injections Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232